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Abstract 
Dioscin, extracted from the root of Polygonatum Zanlanscianense pamp, exhibits cytotoxicity 
towards human myeloblast leukemia HL-60 cells. Proteomic analysis revealed that the 
expression of mitochondrial associated proteins was substantially altered in HL-60 cells 
corresponding to the dioscin treatment, suggesting that mitochondrion is the major cellular 
target of dioscin. Mitochondrial functional studies validated that mitochondrial apoptotic 
pathway was initiated by dioscin treatment. Changes in proteome other than mitochondrial 
related proteins implicate that other mechanisms are also involved in dioscin-induced 
apoptosis in HL-60 cells, including the activity impairment in protein synthesis, alterations of 
phosphatases in cell signaling, and deregulation of oxidative stress and cell proliferation. 
Current study of protein alterations in dioscin-treated HL-60 cells suggested that dioscin 
exerts cytotoxicity through multiple apoptosis-inducing pathways.  
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1. Introduction 
Dioscin (Fig. 1), extracted from the root of Polygonatum Zanlanscianense Pamp, is 
one of saponins (plant glucosides). In some traditional Chinese medicine, saponins are major 
components that have long been used to treat various diseases such as cancers, lung illnesses, 
palpitation, upset stomach and diabetes [1-3]. Recent biological and pharmaceutical 
researches showed that diosgenyl saponins exert a large variety of biological functions, with a 
potential for use in cancer chemoprevention. Dioscin was able to induce cytotoxicity and 
inhibit the growth of human myeloblast leukemia HL-60 cells [3-6] and Hela cells [7]. The 
activation of caspase 9 and 3 together with the down-regulation of anti-apoptotic protein Bcl-
2, demonstrated that the apoptotic signaling triggered by dioscin was mediated through the 
intrinsic mitochondria-dependent pathway [3]. Herein we investigated the protein alternations 
in dioscin-treated HL-60 cells by proteomic approach aiming at globally examining the 
molecular pathways involved in dioscin-induced cytotoxicity.   
 Proteomics is a research technique that can identify, characterize and quantitate 
proteins expressed in cells, tissues or organisms under given conditions such as 
chemotherapeutic drug treatment [8, 9]. The altered proteins identified by proteomic 
approach can be further characterized as potential drug targets and the global analysis of the 
protein alterations can result in valuable information to understand the drug action 
mechanisms. By comparing the protein profiles of HL-60 cells treated by dioscin to untreated 
control, we identified differentially expressed proteins by peptide-mass-fingerprinting (PMF). 
By correlating the proteomic results with other functional studies, the current study provides 
insights into the action mechanism of dioscin as a potential anticancer drug.  
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2. Materials and Methods 
2.1 Dioscin and other reagents 
 Dioscin was provided by Shanghai Institute of Organic Chemistry. All other 
chemicals, except otherwise noted, were purchased from Amersham Biosciences (Uppsala, 
Sweden). Dioscin was dissolved in Dimethyl Sulphoxide DMSO (Sigma) prior to use. 
2.2 Cell lines and culture conditions 
HL-60 cells were cultured in RPMI 1640 medium with 2.0 g/L sodium bicarbonate 
plus 10% fetal bovine serum, 1% L-glutamine, 1% penicillin and streptomycin (100 units/ 
mL). Those two cell lines were maintained in a humidified incubator with an atmosphere of 
95% air and 5% CO2 at 37˚C. When the cells reached ~80% confluence, they were harvested 
and plated for either subsequent passages or drug treatments. Cells were treated with 6.6 
µg/ml dioscin (7.6 µM) for 24 and 48 hours respectively according to the IC50 (Half-maximal 
inhibitory concentration) measured by Mimaki et. al. [4]. After treatment, media was 
discarded and cells were washed twice with ice cold washing buffer (10 µM Tris-HCl, 250 
µM Sucrose, pH 7.0). Cells were then harvested by using a cell scrapper and transferred to a 
clean 2.0 mL Eppendorf tube, spun down at 3,000 rpm for 5 minutes, and then washed twice 
with washing buffer, 1 mL each. Cell pellet was lysed by adding 80 µL lysis solution (8 M 
Urea, 4% CHAPS, 2% IPG buffer, 0.2 mg/mL PMSF). After centrifuged at 14,000 rpm for 10 
minutes at 4˚C to clarify the cell lysate, the lysis supernatant was used for 2-DE.  
2.3 Morphological changes.     
To detect morphological changes in apoptosis process, nuclear staining was 
performed with 1 µg/ml DAPI, and cells were analyzed by a fluorescence microscope 
(Olympus IX71 CTS Chinetek Scientific Microscope).  
2.4 Flow cytometric analysis of apoptosis.     
Dioscin-induced apoptosis was determined with flow cytometry according to the 
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method previously described [10]. Cells were cultivated for 24 h before either left untreated 
or treated with 7.6 µM of Dioscin. At the end of each experiment, cells were harvested, 
resuspended in PBS solution, stained by propidium iodide (PI), and analyzed with a FACStar 
Plus flow cytometer. For each sample 1 × 106 cells were analyzed, providing a solid statistical 
basis for the determination of the percentage of apoptotic cells in each treatment using the 
WinMDI 2.8 software program. 
2.5 Two-dimensional electrophoresis (2-DE) 
        2-DE was performed with Amersham Biosciences (Uppsala, Sweden) IPGphor IEF and 
Ettan Dalt Six electrophoresis units using the protocol suggested by the manufacturer. Briefly, 
80 µg of cell whole protein was mixed up to 250 µL of rehydration solution (8 M Urea, 4% 
CHAPS, 1 mM PMSF, 20 mM DTT and 0.5% IPG buffer). The rehydration step was carried 
out with precast 13 cm IPG strips for more than 12 h at low voltage of 30 V. IEF was run 
following a step-wise voltage increase procedure: 500 V and 1000 V for 1 h each and 5000-
8000 V for about 10 h with a total of 64 KVh. After IEF, the strips were subjected to two-step 
equilibration in equilibration buffers (6 M Urea, 30% Glycerol, 2% SDS and 50 mM Tris-
HCl pH 6.8) with 1% DTT (w/v) for the first step, and 2.5% Iodoacetamide (w/v) for the 
second step. The strips were then transferred onto the second-dimensional SDS-PAGE that 
was run on 1.5 mm thick 12.5% polyacrylamide gels. 
2.6 Silver staining 
        The gels were fixed with 40% ethanol and 10% acetic acid overnight, and then 
incubated in a buffer solution containing 30% ethanol, 4.1% sodium acetate and 0.2% sodium 
thiosulfate for 30 minutes. After washing three times in water for 5 minutes each, the gels 
were stained in 0.1% silver nitrate solution containing 0.02% formaldehyde for 40 minutes. 
Development was performed for 15 minutes in a solution consisting of 2.5% sodium 
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carbonate and 0.01% formaldehyde. EDTA solution (1.46%) was used to stop the 
development and the stained gels were then washed three times in water for 5 minutes each. 
2.7 Image acquisition and analysis 
        The stained gels were scanned in an Image Scanner (Amersham Biosciences) operated 
by the software, Lab Scan 3.00, also from Amersham Biosciences. Intensity calibration was 
carried out using an intensity step wedge prior to gel image capture. Image analysis was 
carried out using the Image Master 2D Elite software 2003.02 (Amersham Biosciences). 
Image spots were initially detected, matched and then manually edited. Each spot intensity 
volume was processed by background subtraction and total spot volume normalization; the 
resulting spot volume percentage was used for comparison. Only those significantly different 
spots (over two fold up or down regulate) were selected for analysis by mass spectrometry. 
2.8 Tryptic in-gel digestion 
Protein spots were excised and transferred into siliconized 1.5 mL Eppendorf tubes. Gel 
chips were distained in a 1:1 solution of 30 mM potassium ferricyanide and 100 mM sodium 
thiosulfate and then equilibrated in 50 mM ammonium bicarbonate to pH 8.0. After hydrating 
with acetonitrile and drying in a Speed Vac, the gels were rehydrated in a minimal volume of 
trypsin solution (10 µg/mL in 25mM NH4HCO3) and incubated at 37˚C overnight. The 
supernatant was directly applied onto the sample plate with equal amount of matrix. If 
necessary, the in-gel digests were extracted subsequently with 50% and 80% acetonitrile, and 
then concentrated and desalted by Zip Tips (Millipore, Bedford, MA, USA) prior to applying 
on to the sample plate. 
2.9 MALDI-TOF MS and protein identification 
        Tryptic peptide mass spectra were obtained using a Voyage-DE STR MALDI-TOF mass 
spectrometer (Applied Biosystems, Foster City, CA, USA). The instrument setting was 
reflector mode with 175 ns delay extraction time, 60-65% grid voltage, and 20 kV 
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accelerating voltage. Laser shots at 250 per spectrum were used to acquire the spectra with 
mass range from 600-2500 Da. The trypsin autolytic fragment peaks (906.5049, 1153.5741 
and 2163.0570) served as internal standards for mass calibration. Protein identification was 
performed by searching the NCBInr protein database using MS-Fit 
(http://prospector.ucsf.edu/). The criteria for searching were set at 50 ppm or better mass 
accuracy, at least four matching peptide massed and Mr and pI matching estimated values 
form gels. Post source decay MS/MS measurement and MS-Tag                         
( http://prospector.ucsf.edu/ ) searching were also performed to confirm the results from MS-
Fit. Species search was limited to Homo sapiens. 
2.10 Mitochondrial transmembrane potential (∆Ψm)   
Changes in mitochondrial transmembrane potential were assayed as described by 
Huigsloot et al [11]. Briefly, after treatment with dioscin for a period of time as indicated, 
cells were washed twice in HBSS, and incubated with 1 µM Rho-123 (Molecular Probes, 
Eugene, OR) for 30 min at 37°C. Cells were then washed in HBSS, and resuspended in 1 mL 
PBS for analysis. Rho-123 (Molecular Probes, Eugene, OR, USA) is taken up selectively by 
mitochondria [12, 13], and the extent of uptake depends on ∆Ψm. Rho-123 fluorescence was 
measured using a fluorescence-activated cell sorter (Coulter FACS) with excitation and 
emission wavelengths of 488 and 530 nm. A total of over 10,000 events were analyzed. 
2.11 Western blot analysis.     
Western blot analysis was performed using primary antibodies against p53 (Santa 
Cruz), pro-caspase 3 (Santa Cruz), and Bcl-2 (Santa Cruz) respectively at optimal dilution. A 
nonspecific band from p53 probe was taken as a marker for equal protein loading. 
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3. Results  
Diosin cytotoxicity in HL-60 cells was first verified by morphological observation. 
Figure 2 shows the morphological changes of HL-60 cells treated with dioscin (7.6 µM) at 
different time points. Typical apoptotic changes in nuclear were observed in HL-60 cells after 
dioscin treatment for 16 h, and the number of condensed nucleus increased dramatically after 
24 h treatment (Fig. 2A). The numbers of apoptotic cells were quantitated and presented as 
percentages in Figure 1B.  
The effect of dioscin on cell death was further investigated by flow cytometric 
analysis (Fig. 3). The percentage of the apoptotic cells after dioscin treatment was higher than 
that in the untreated control cells in a time dependent manner (Fig. 3), with significantly 
increased apoptosis beginning from 16 h drug treatment, consistent with the results obtained 
from DAPI staining (Fig. 2). Based on these results, the treatment condition with dioscin 7.6 
µM for 24 and 48 h, respectively, was selected for the following proteomic analysis. 
 Figure 4 shows a pair of representative 2D gel images for whole cell proteins 
extracted from HL-60 cells with and without dioscin treatments for 24 h. Proteins were well 
separated in the 2D gels in the ranges of Mr 6 – 200 kD and pI 3 – 10. Image analysis 
revealed that a number of protein spots were significantly altered in terms of volume intensity. 
Highlighted in circles are the locations where protein alterations were detected. Table 1 lists 
the proteins’ name identified through peptide mass fingerprinting (PMF), together with the 
spot number, experimental molecular weights and pIs, their reported functions and fold 
differences of alterations corresponding to the dioscin treatments for 24 and 48 hours. Overall, 
the protein alterations are quite substantial, with fold differences ranging from 2 to 20 folds 
and consistent changes were observed in both 24 and 48 hour treatments. Table 2 summarizes 
the parameters resulted from PMF, showing the high mass accuracy and matching scores.  
 These altered proteins can be classified into several categories according to their 
known functions. The first group is mitochondrial-related proteins, including the dramatic 
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increase in the mitochondrial precursors of fumarate hydratase, heat shock protein 60, 
chaperonin GroEL, ATP synthase alpha and beta chains, and the significant down-regulation 
of Rho GDP-dissociation inhibitor 1 and 2 (Rho GDIs) and alpha- and beta-tubulins (Table 1 
and Fig. 5). The second group of altered proteins involves protein phosphorylation, including 
the under-expression of protein-tyrosine phosphatase MEG2 (PTPase), dUTP diphosphatase 
(dUTPase) and inorganic pyrophosphatase (PPase) and the increase of a fragment of ER 
luminal calcium-binding protein GRP78 (Table 1 and Fig. 6). The third group of proteomic 
changes contains the down regulation of the nuclear and RNA binding proteins, including 
RNA-binding protein 28, transformation upregulated nuclear protein and heterogeneous 
nuclear ribonucleoprotein H (hnRNP H) (Table 1 and Fig. 7). Other protein alterations 
induced by dioscin include the significant increase of oxidoreductase UCPA, beta 
tropomyosin and HEI-C and the remarked decrease of glutathione transferase (Table 1 and 
Fig. 8).  
 Corresponding to the proteomic changes of mitochondrial proteins, mitochondrial 
membrane depolarization was measured to test the mitochondrial integrity. In the apoptotic 
process, the mitochondrial outer membrane becomes permeable, following by releasing 
cytotoxic proteins from the mitochondrial to the cytosal, and subsequently activated capases 
[14]. Using Rho-123 as a marker to determine mitochondrial permeabilization, flow 
cytometric studies showed that the mitochondrial membrane integrity depleted gradually until 
24 hour treatment of dioscin (Fig. 9).  
Western blot analysis of the mitochondria-associated apoptotic proteins (Fig. 4) 
revealed that pro-caspase 3 in HL-60 cells disappeared after dioscin treatment for 24 hours, 
indicating that caspase 3 was activated by the drug treatment. The expression of p53 was 
detected in 24 and 48 hours treatment of dioscin, and the expression of Bcl-2, the anti-
apoptotic protein, was suppressed by dioscin treatment.  
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4. Discussion 
4.1 Dioscin induced apoptosis in HL-60 cells  
Natural products are important sources of drugs for the development of novel 
chemotherapeutics. Diosgenyl saponins are often found as the major components in 
traditional Chinese medicines, and dioscin is one of the best known diosgenyl saponin [7]. 
Dioscin has been reported to induce apoptosis in a number of cancer cell lines [3, 7]; 
however, the detailed mechanisms of dioscin-induced cell death is still unclear. Apoptosis is 
the process of eliminating unwanted cells in biological systems, and is one of the key 
mechanisms for chemotherapeutic drugs. There are numbers of typical hallmarks of apoptotic 
cells, including DNA chromatin fragmentation, DNA laddering, nucleus condensation and 
PARP-1 cleavage [15, 16]. Figures 2 & 3 showed that dioscin treatment caused marked 
changes in nuclear morphologies (Fig. 2) and increased the number of cells in the sub-G1 
peak (Fig. 3), suggesting that dioscin exerts cytotoxicity by inducing apoptosis leading to cell 
death in HL-60 cells.  
4.2 Mitochondria is a major target of dioscin cytotoxicity 
The substantial alterations of mitochondrial proteins in the dioscin treatment indicate 
that mitochondrion is a major target of dioscin which impairs the mitochondrial function. The 
mitochondrial damage induced by dioscin treatment appears the reason for the amount 
increase of many mitochondrial protein precursors. These proteins may be released from 
mitochondria before being converted into mature forms due to the mitochondrial dysfunction. 
This means that the amounts of the functional mitochondrial proteins may be diminished, 
leading to the decrease of the proteins such as tubulins and Rho GDIs whose proper folding 
and functioning depend on the mitochondrial proteins. It is well known that mitochondrial 
HSPs can work cooperatively to bind and fold tubulins and Rho GDIs into the functional 
molecules [17, 18]. The mitochondrial dysfunction is probably presented as the depletion of 
mitochondrial potential, as discussed as follows. 
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Recent studies suggested that mitochondrion plays a central role in the apoptotic 
process [19]. Once apoptotic signals reached mitochondrion, the outer membrane became 
permeabilized, releasing apoptotic proteins, for example, cytochrome c and apoptosis 
inducing factor (AIF), into the cytosol, cytochrome c thus activates executioner caspases, 
while AIF translocates into the nucleus to activate nucleases, followed by DNA fragmentation, 
leading to the morphological and biochemical changes characteristic of apoptotic cell death 
[20, 21]. Our findings of the depletion of the mitochondrial potential detected 24 hours after 
treatment of dioscin suggests that dioscin induced apoptosis via mitochondrial initiated death 
pathways (Fig. 9), followed by the activation of procaspase 3 (Fig. 10).     
          Biswas et al have reported that once the mitochondrion became permeabilized, a 
number of nuclear gene targets including those involved in Ca2+ storage/release (RyR1, 
calreticulin, calsequestrin), glucose metabolism (hexokinase, pyruvate kinase, Glut4), 
oncogenesis (TGF-β1, cathepsin L, IGFR1, melanoma antigen) and apoptosis (Bcl-2, Bid, 
Bad, p53) are upregulated [22]. p53 is a sequence-specific transcription factor that plays a 
pivotal role in cellular responses to a variety of genotoxic stresses, which result in cell cycle 
arrest and/or apoptosis [23, 24]. Our data (Fig. 10) showed that p53 expression was 
significantly up-regulated after mitochondrial membrane potential depletion in response to 
dioscin treatment. This result indicates that p53 participate in dioscin induced apoptosis 
downstream of mitochondrion. Bcl-2 family proteins contains anti-apoptotic (Bcl-2 and Bcl-
xL) and pro-apoptotic proteins (Bax and Bad) [25]. Once activated, Bax is inserted into the 
mitochondrial outer membrane and increases membrane permeability. On the other hand, the 
anti-apoptotic protein, Bcl-2 inhibits this process, and the balance of Bax and Bcl-2 could 
decide cell fate of death or survival [26]. The down-regulated Bcl-2 expression as shown in 
Figure 10 together with the undetectable Bax (data not shown) suggests that the 
mitochondrial permeabilization is mediated by the regulation of the Bcl-2 family proteins in 
dioscin treated HL 60 cells. 
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4.3 Other pathways involved in dioscin cytotoxicity 
Proteomic changes other than mitochondrial related proteins implicate that other 
pathways are also involved in the dioscin cytotoxicity. Dioscin treatment caused the down 
regulation of several phosphatases (Table 1), suggesting that dioscin may target the cellular 
signaling pathways, causing the suppression of protein phosphorylation, and leading to the 
growth inhibition of HL-60 tumor cells. Protein phosphorylation triggers a wide range of 
cellular signaling pathways that regulate various cellular activities including protein synthesis 
and cell proliferation. Active protein phosphorylations are thus essential processes for the 
rapid growth of tumor cells. Dioscin may exert its cytotoxicity by retarding the protein 
phosphorylation. The increase of the signaling protein fragment (grp78, Table 1) may implicate 
that the functional phosphoralytion enzyme was degraded during the drug treatment. 
The impaired activity of protein synthesis in dioscin treatment can also be derived 
from the observation of the down regulation of the nuclear and RNA binding proteins (Table 
1). These proteins work closely together in protein synthesis process, which is required in cell 
proliferation and growth. Clearly, dioscin treatment somehow affects the nuclear function and 
inhibits the protein synthesis process, presenting in the form of the significant suppression of 
the RNA related proteins. Again, we detected a large increase of a fragment of PAI-1 mRNA-
binding protein, suggesting that protein degradation may occur during the drug action. In 
addition, glutathione transferase is needed to suppress oxidative oxygen species during 
metabolism and oxidoreductase is an active enzyme in oxidative stress signaling process. The 
substantial increase of oxidoreductase and the marked decrease of glutathione transferase 
imply that dioscin treatment actively stimulates the oxidative stress in the leukemia tumor 
cells, leading to the apoptosis of cell death.  
 In conclusion, our present experimental results verified that dioscin causes apoptosis 
of HL-60 cells through nuclear condensation and cell cycle arrest. Proteomic data and 
mitochondrial functional studies confirmed that mitochondrion is a major target of dioscin. 
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We further demonstrated that dioscin treatment induces the increase of mitochondrial 
permeability (mitochondrial potential depletion), leading to the release of mitochondrial 
functional protein precursors and death initiating proteins. In addition, the dioscin targets also 
include phosphorylation cellular signaling, RNA-related protein synthesis and oxidative 
stress processes. These pathways may work complementarily resulting in the severe 
cytotoxicity of dioscin towards the cancer cells.  
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Table 1. Proteins and their alterations after dioscin treatment. Fold differences were calculated based on the image analysis of silver-staining 
gels. 
Spot # Protein ID (MW/pI) Experimental 
(MW/pI) 
Reported function Fold diff.  
(24 hr) 
Fold diff. 
(48 hr) 
368 Fumarate hydratase, mitochondrial precursor (Fumarase), (54.6 kD/8.8) 54 kD/8.0 Mitochondrial related +2.1 +2.5 
222 Heat shock protein 60, mitochondrial precursor (Hsp60), (61.1 kD/5.7) 60 kD/5.3 Stress-related, chaperone +2.3 +2.8 
1215 Heat shock protein 60, mitochondrial precursor (Hsp60), (61.1 kD/5.7) 60 kD/5.2 Stress-related, chaperone +6.2 +4.3 
297 chaperonin GroEL precursor, mitochondrial matrix protein, (61.1 kD/5.7) 51 kD/5.5 Mitochondrial related +15.1 +20.0 
322 ATP synthase beta chain, mitochondrial precursor (56.6 kD/5.3) 50 kD/5.2 Mitochondrial related +2.8 +3.5 
1255 ATP synthase alpha chain, mitochondrial precursor (59.8 kD/9.2) 60 kD/8.0 Mitochondrial related +4.0 +4.4 
844 Rho GDP-dissociation inhibitor 1 (Rho GDI 1), (23.2 kD/5.0) 23 kD/4.9 Cell differentiation -3.0 -5.1 
868 Rho GDP-dissociation inhibitor 2 (Rho GDI 2), (23.0 kD/5.1) 23 kD/5.0 Cell differentiation -7.5 -5.5 
271 alpha-tubulin, (50.2 kD/4.9) 50 kD/4.9 Cytoskeleton protein -8.5 -8.3 
285 beta-tubulin, (48.9 kD/4.7) 50 kD/4.7 Cytoskeleton protein -3.4 -3.5 
      
350 Protein-tyrosine phosphatase MEG2 (PTPase-MEG2), (68.0 kD/8.2) 48 kD/6.8 Signaling -3.9 -10.3 
1030 dUTP diphosphatase (dUTPase), (17.7 kD/6.2) 18 kD/5.8 Signaling -4.1 -9.1 
1236 Inorganic pyrophosphatase (PPase), (32.7 kD/5.5) 32 kD/5.5 Signaling -3.6 -6.3 
878 ER lumenal Calcium-binding protein grp78, (72.3 kD/5.1) (N-fragment) 23 kD/5.0 Signaling +2.1 +2.0 
547 Phosphopyruvate hydratase, alpha, (47.2 kD/7.0) 35 kD/5.7 Signaling -2.5 -3.0 
      
140 RNA-binding protein 28 (85.7 kD/9.3) 85 kD/7.8 Protein synthesis -4.0 -6.6 
207 Transformation upregulated nuclear protein (51 kD/5.2) 55 kD/5.2 Protein synthesis -3.7 -3.5 
312 Heterogeneous nuclear ribonucleoprotein H (hnRNP H), (49.2 kD/5.9) 48 kD/5.9 Protein synthesis -2.7 -4.8 
852 PAI-1 mRNA-binding protein (42.4 kD/8.4) (Fragment) 23 kD/5.0 Protein synthesis +4.8 +5.5 
      
1081 Oxidoreductase UCPA, (26.7 kD/7.6) 15 kD/5.0 Oxidative  +8.1 +8.5 
931 Glutathione transferase, (23.4 kD/5.4) 21 kD/5.3 Oxidative  -2.5 -3.1 
      
919 beta tropomyosin (29.9 kD/4.7) 22 kD/5.1 Cell proliferation +5.1 +7.9 
935 Coiled-coil domain containing protein 5 (Enhancer of invasion-cluster) 
(HEI-C), (31.9 kD/5.4) 
21 kD/5.8 Mitosis +2.7 +3.0 
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Table 2. Results of MALDI-TOF mass spectra and database searching for protein identification 
Spot # Protein ID (MW/pI) Acc # 
(NBCI) 
Peptides 
matched 
Sequence 
coverage (%) 
Total mass 
error (ppm) 
MOWSE  
score 
368 Fumarate hydratase, mitochondrial precursor (Fumarase), (54.6 kD/8.8) 1730117 7 16 19 671 
222 Heat shock protein 60, mitochondrial precursor (Hsp60), (61.1 kD/5.7) 129379 17 28 24 1037 
1215 Heat shock protein 60, mitochondrial precursor (Hsp60), (61.1 kD/5.7) 129379 41 53 18 3.14e+09 
297 chaperonin GroEL precursor, mitochondrial matrix protein, (61.1 kD/5.7) 129379 7 23 14 779 
322 ATP synthase beta chain, mitochondrial precursor (56.6 kD/5.3) 114549 20 28 15 7.15e+07 
1255 ATP synthase alpha chain, mitochondrial precursor (59.8 kD/9.2) 114517 8 18 10 1226 
844 Rho GDP-dissociation inhibitor 1 (Rho GDI 1), (23.2 kD/5.0) 1707892 11 57 25 1430 
868 Rho GDP-dissociation inhibitor 2 (Rho GDI 2), (23.0 kD/5.1) 1707893 8 37 19 2411 
271 alpha-tubulin, (50.2 kD/4.9) 2119266 M 10 22 17 1.44e+05 
285 beta-tubulin, (48.9 kD/4.7) 18088719 25 37 15 1.72e+07 
       
350 Protein-tyrosine phosphatase MEG2 (PTPase-MEG2), (68.0 kD/8.2) 1172724 6 17 33 220 
1030 dUTP diphosphatase, mitochondrial precursor (dUTPase), (17.7 kD/6.2) 3041664 7 46 20 845 
1236 Inorganic pyrophosphatase (PPase), (32.7 kD/5.5) 8247940 5 17 32 161 
878 ER lumenal Ca(2+) binding protein grp78, (72.3 kD/5.1) (N-fragment) 87528 10 16 22 3800 
547 phosphopyruvate hydratase, alpha, (47.2 kD/7.0) 693933 8 12 19 771 
       
140 RNA-binding protein 28 (85.7 kD/9.3) 55976611 7 11 18 237 
207 transformation upregulated nuclear protein (51 kD/5.2) 631470 6 15 29 441 
312 Heterogeneous nuclear ribonucleoprotein H (hnRNP H), (49.2 kD/5.9) 1710632 11 23 19 7.17e+04 
852 PAI-1 mRNA-binding protein (42.4 kD/8.4) (Fragment) 55665495 5 19 7 283 
       
1081 Oxidoreductase UCPA, (26.7 kD/7.6) 130348 12 41 18 5.08e+05 
931 Glutathione transferase, (23.4 kD/5.4) 121746 6 50 34 1.65e+04 
       
919 beta tropomyosin (29.9 kD/4.7) 6573280 6 28 22 465 
935 Coiled-coil domain containing protein 5 (Enhancer of invasion-cluster) 
(HEI-C), (31.9 kD/5.4) 
50400607 6 18 31 524 
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Figure Legends 
Figure 1. The chemical structure of dioscin. 
Figure 2. Morphological changes of HL-60 cells induced by dioscin.  
A. Typical apoptotic morphological changes were detected in dioscin-treated HL-
60 cells. The cells were stained with DAPI and visualized by fluorescent microscope (× 
320 magnificence).  
B. Percentage of apoptotic HL-60 cells under dioscin-treatment. 
Figure 3. Flow cytometric analysis indicated that dioscin induced apoptosis in HL-60 
cells. 
Figure 4. An overview of the master 2D gel images for HL-60 cell extracts. Highlighted 
in circles are the areas where significant and consistent differences were found in protein 
expression level.  
Figure 5. Detailed alteration patterns of mitochondrial related proteins.  
Figure 6. Detailed alteration patterns of the proteins involved in signaling pathways. 
Figure 7. Detailed alteration patterns of RNA-binding proteins involved in protein 
synthesis. 
Figure 8. Detailed alterations of proteins involved in oxidative stress and cell 
proliferation. 
Figure 9. Measurement of mitochondrial membrane depolarization in dioscin-treated 
HL-60 cells by Rho-123 staining. 
Figure 10. Western blotting analysis of apoptosis regulating proteins, including p53, pro-
caspase 3, and Bcl-2, in dioscin-treated HL-60 cells, using a non-specific band from p53 
probe as internal loading control. 
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